tbuckley/cabot-search huggingface dataset:
Aptamer Internalization via Endocytosis Inducing S-Phase Arrest and Priming Maver-1 Lymphoma Cells for Cytarabine Chemotherapy
Authors: Huan Li, Shuanghui Yang, Ge Yu, Liangfang Shen, Jia Fan, Ling Xu, Hedong Zhang, Nianxi Zhao, Zihua Zeng, Tony Hu, Jianguo Wen, Youli Zu
Journal: Theranostics (2017)

The goal of precision therapy is to efficiently treat cancer without side effects.Aptamers are a class of small ligands composed of single-stranded oligonucleotides that bind to their targets with high affinity and specificity.In this study, we identified an ssDNA aptamer specifically targeting Maver-1 lymphoma cells with high binding affinity (K d = 70±8 pmol/L).Interestingly, cellular cycle studies revealed that exposure of Maver-1 cells to synthetic aptamers triggered S-phase arrest of 40% of the cells (vs.18% baseline).Confocal microscopy confirmed specific cell binding of aptamers and the resultant endocytosis into Maver-1 cells.Subsequent functional assays validated the fact that aptamer internalization into targeted cells is a prerequisite for Maver-1 cell growth inhibition.Importantly, aptamer-induced S-phase arrest induced enhanced chemotherapeutic results involving cytarabine, which primarily kills lymphoma cells at S-phase.Combination treatments revealed that aptamer re-exposure considerably primed Maver-1 cells for cytarabine chemotherapy, thus achieving a synergistic killing effect by reaching cell death rates as high as 61% (vs.13% or 14% induced by aptamer or cytarabine treatment alone).These findings demonstrated that aptamers do not only act as molecular ligands but can also function as biotherapeutic agents by inducing S-phase arrest of lymphoma cells.In addition, logical combination of aptamer and cytarabine treatments ushers the way to a unique approach in precision lymphoma chemotherapy.
IMPACT ON LONG TERM MORTALITY OF PERSISTENT PULMONARY HYPERTENSION AFTER TRANSCATHETER AORTIC VALVE IMPLANTATION
Authors: Maria I. Drakopoulou, Konstantinos Toutouzas, Archontoula Michelongona, Konstantinos Stathogiannis, George Latsios, Andreas Synetos, Styliani Brili, Odysseas Kaitozis, Eleftherios Tsiamis, Dimitris Tousoulis
Journal: Journal of the American College of Cardiology (2017)
NON-ALCOHOLIC FATTY LIVER DISEASE IN CORONARY ARTERY DISEASE PATIENTS: ASSOCIATION WITH IMPAIRED GLUCOSE METABOLISM AND WITH FUTURE CARDIOVASCULAR EVENT RISK
Authors: Christoph H. Saely, Daniela Zanolin, Alexander Vonbank, Andreas Leiherer, Philipp Rein, Heinz Drexel
Journal: Journal of the American College of Cardiology (2017)
APELIN-13 CO-TREATMENT WITH UMBILICAL CORD BLOOD-DERIVED MESENCHYMAL STEM CELLS IMPROVES ENGRAFTED CELL SURVIVAL AND INHIBITS MACROPHAGE ACTIVATION IN PULMONARY ARTERIAL HYPERTENSION MURINE MODEL
Authors: Albert Jang, Seyeon Oh, Seungbum Choi, Sehyun Chae, Jeongsik Moon, Minsu Kim, Pyung Chun Oh, Kyunghoon Lee, Kuk Hui Son, Daehee Hwang, Kyunghee Byun, Wook-Jin Chung
Journal: Journal of the American College of Cardiology (2017)
Examining patient choices for metastatic breast cancer drugs.
Authors: Mary Lou Smith, Carol B White, Elda Railey, Anna Maria Storniolo, George W. Sledge
Journal: Journal of Clinical Oncology (2012)

6053 Background: Patients with metastatic breast cancer face difficult drug decisions. Our previous research (ASCO Proc 2011, abstr 6044) focused on general benefit and toxicity showed that conjoint analysis (CA) allows patients to express preferences; our current research quantifies patient preference for specific drug profiles (capecitabine and paclitaxel). Methods: Research Advocacy Network and CBWhite conducted research using CA for DOD Center of Excellence for Individualization of Therapy in Breast Cancer. An online survey was sent by four breast cancer organizations (N=641). Questions elicited views on trade-offs between benefit and type/severity/duration of toxicity. CA questions present pairs of hypothetical treatments and ask respondents their preferred alternative; a follow-up question asks whether the person would take the treatment if it were the only option available. Analysis of response patterns allows study of treatment preferences for combinations of benefit and described toxicity. Results: See table. Preferences show much greater attention to benefit than to toxicity. When CA is used to examine impact of biomarkers, focus on benefit continues. Paclitaxel profile (IV) set with moderate PN lasting 1 year post treatment: with 33% benefit LH, 6% of respondents change treatment decision if biomarker predicts 27% vs 60% toxicity likelihood; with 27% toxicity LH, 22% of respondents change treatment decision if biomarker predicts 20% vs 50% benefit likelihood. Conclusions: For patients with metastatic disease, CA shows much greater attention to benefit than toxicity, and high likelihood to take treatment with at least 30% chance of benefit for any toxicity tested here. These results suggest biomarkers (for the profiled drugs) predicting benefit are more likely to be used to affect patient treatment decisions than biomarkers for toxicity. [Table: see text]
MANAGEMENT OF CARDIOVASCULAR DISEASE IN SUB-SAHARAN AFRICA: DATA FROM THE HAALSI (HEALTH AND AGING IN AFRICA: LONGITUDINAL STUDIES OF INDEPTH COMMUNITIES) STUDY
Authors: Thiago Jardim, Sheridan Reiger, Stephen Tollman, F. Xavier Gomez-Olive, Alisha Wade, Ryan Wagner, Thomas Gaziano
Journal: Journal of the American College of Cardiology (2017)
GLYCEMIC CONTROL IN INSULIN AND NON-INSULIN DEPENDENT DIABETIC PATIENTS WITH ST ELEVATION MYOCARDIAL INFARCTION PREDICTS TIME TO PRESENTATION
Authors: Jonathan Evans, Tigran Khachatryan, David Hamilton, Andrew Stewart, Daniel Amponsah, Eric Suh, Kenneth Jutzy, Islam Abudayyeh, Anthony Hilliard
Journal: Journal of the American College of Cardiology (2017)
Hospitals to get £800m earmarked for GPs and mental health
Authors: Gareth Iacobucci
Journal: BMJ (2017)

Millions of pounds in funding earmarked for mental health, community health, and primary care services is to be diverted to plug acute care hospitals’ deficits this year, it has emerged.

In a letter to clinical commissioning groups obtained by the Health Service Journal ,1 NHS England’s chief finance officer, Paul Baumann, confirmed that an £800m (€920m; $980m) contingency fund that was stripped out of clinical commissioning groups’ budgets in 2016-17 will be retained in full by the Department of Health to help reduce the overall deficit that largely stems from hospitals.

NHS trusts in …
CLINICAL STUDY OF THE IMPACT OF PREEXISTING PATIENT-PROSTHESIS MISMATCH ON VALVE-IN-VALVE PERFORMANCE
Authors: Anne-Sophie Zenses, Abdellaziz Dahou, Josep Rodes-Cabau, Marie-Annick Clavel, Robert De Larochellière, Jean-Michel Paradis, Daniel Doyle, Siamak Mohammadi, Eric Dumont, Chekrallah Chamandi, Tania Rodriguez-Gabella, Erwan Salaun, Régis Rieu, Philippe Pibarot
Journal: Journal of the American College of Cardiology (2017)
Fulvestrant (FUL) Plus Enzastaurin (ENZA) vs FUL Plus Placebo (PBO) in Aromatase Inhibitor (AI)-Resistant Metastatic Breast Cancer (MBC): A Randomized, Double-Blind, Phase 2 Trial
Authors: R.S. De Jong, G.S. Sonke, N. Maass, K. Mansouri, L. Cirri, P. Shi, O. Hamid, G. Mariani
Journal: Annals of Oncology (2012)
Evaluation of computational tools to determine prognostic significance of <i>TP53</i> mutation in head and neck squamous cell carcinoma (HNSCC).
Authors: David Masica, Shuli Li, Chris Douville, Judith Manola, Robert L. Ferris, Barbara Burtness, Arlene A. Forastiere, Wayne Koch, Rachel Karchin, Christine H. Chung
Journal: Journal of Clinical Oncology (2014)

6035 Background: TP53 is the most commonly mutated gene in HNSCC. The specific mutations in TP53 can be prognostic of patient survival. Thus, a framework to predict patient survival from previously uncharacterized mutation in TP53 is valuable. There are many computational tools for predicting the phenotypic impact of genetic variation, but the overall clinical value of these algorithms remains unclear. Methods: Sixteen different models to predict HNSCC patient survival based on TP53 mutations were assessed using the TP53 mutation and clinical data from ECOG 4393 [Poeta, M. L., et al. NEJM (2007) 357(25) 2552-2561]. These models include: server-based computational tools SIFT, PolyPhen-2, and Align-GVGD; our in-house POSE and VEST algorithms; the rules devised in Poeta et al.1 with and without considerations for splice-site mutations; location of mutation in the DNA-bound TP53 protein structure; and a functional assay measuring WAF1 transactivation in TP53-mutated yeast. Results: We assessed model performance using overall survival (OS) and progression-free survival (PFS) from 420 HNSCC patients, of whom 224 had TP53 mutations. Each mutation was categorized as “disruptive” or “non-disruptive”. For each model, we compared the outcome between the predicted disruptive group vs. the non-disruptive group. The rules devised by Poeta et al. 1 (disruptive mutations: non-conservative mutations in the key DNA-binding domain, or stop codons vs. non-disruptive mutations: all mutations excluding the disruptive mutations) with or without our modification were observed to be superior to others. While the differences in OS (disruptive vs. non-disruptive) appear to be marginally significant (Poeta rule+modification, p=0.089; Poeta rule: p=0.053), both algorithms identified a disruptive group that has significantly worse PFS outcome (Poeta rule+modification, p=0.011; Poeta rule, p=0.027). Conclusions: In general, prognostic performance was low among the computational methods assessed here. Further studies are required to develop and validate computational models that can predict functional and clinical significance of TP53mutations in HNSCC patients.
ASSOCIATION OF CORONARY ARTERY CALCIUM WITH INCIDENT PERIPHERAL ARTERY DISEASE: THE MULTI-ETHNIC STUDY OF ATHEROSCLEROSIS
Authors: Zahra Meyghani, Hooman Bakhshi, Bharath Ambale Venkatesh, Yoshiaki Ohyama, Colin O. Wu, Matthew Budoff, Christina L. Wassel, Michael Criqui, David Bluemke, Joao Lima
Journal: Journal of the American College of Cardiology (2017)
SPHINGOSINE-1 PHOSPHATE IS A NOVEL BIOMARKER THAT CORRELATES WITH STEM CELL MOBILIZATION AND CLINICAL OUTCOMES IN PATIENTS WITH ST-ELEVATION MYOCARDIAL INFARCTION
Authors: Mohammad Mathbout, Ahmed Asfour, Yuri Klyachkin, Himi Tripathi, Ahmed Abdel-Latif, Khaled Ziada
Journal: Journal of the American College of Cardiology (2017)
WHAT IS THE IMPACT OF COMPLICATIONS DURING THE INDEX HOSPITALIZATION ON RESOURCE UTILIZATION DURING THE 90-DAY FOLLOW-UP PERIOD ASSOCIATED WITH CABG SURGERY AMONG MEDICARE BENEFICIARIES?
Authors: Phillip P. Brown, Aaron Kugelmass, David Cohen, Matthew Reynolds, Marc Katz, Michael Schlosser, April Simon, Steven Culler
Journal: Journal of the American College of Cardiology (2017)
Early Positron Emission Tomography Response–Adapted Treatment in Stage I and II Hodgkin Lymphoma: Final Results of the Randomized EORTC/LYSA/FIL H10 Trial
Authors: Marc P.E. André, Théodore Girinsky, Massimo Federico, Oumédaly Reman, Catherine Fortpied, Manuel Gotti, Olivier Casasnovas, Pauline Brice, Richard van der Maazen, Alessandro Re, Véronique Edeline, Christophe Fermé, Gustaaf van Imhoff, Francesco Merli, Réda Bouabdallah, Catherine Sebban, Lena Specht, Aspasia Stamatoullas, Richard Delarue, Valeria Fiaccadori, Monica Bellei, Tiana Raveloarivahy, Annibale Versari, Martin Hutchings, Michel Meignan, John Raemaekers
Journal: Journal of Clinical Oncology (2017)

Purpose Patients who receive combined modality treatment for stage I and II Hodgkin lymphoma (HL) have an excellent outcome. Early response evaluation with positron emission tomography (PET) scan may improve selection of patients who need reduced or more intensive treatments. Methods We performed a randomized trial to evaluate treatment adaptation on the basis of early PET (ePET) after two cycles of doxorubicin, bleomycin, vinblastine, and dacarbazine (ABVD) in previously untreated-according to European Organisation for Research and Treatment of Cancer criteria favorable (F) and unfavorable (U)-stage I and II HL. The standard arm consisted of ABVD followed by involved-node radiotherapy (INRT), regardless of ePET result. In the experimental arm, ePET-negative patients received ABVD only (noninferiority design), whereas ePET-positive patients switched to two cycles of bleomycin, etoposide, doxorubicin, cyclophosphamide, vincristine, procarbazine, and prednisone (BEACOPPesc) and INRT (superiority design). Primary end point was progression-free survival (PFS). Results Of 1,950 randomly assigned patients, 1,925 received an ePET-361 patients (18.8%) were positive. In ePET-positive patients, 5-year PFS improved from 77.4% for standard ABVD + INRT to 90.6% for intensification to BEACOPPesc + INRT (hazard ratio [HR], 0.42; 95% CI, 0.23 to 0.74; P = .002). In ePET-negative patients, 5-year PFS rates in the F group were 99.0% versus 87.1% (HR, 15.8; 95% CI, 3.8 to 66.1) in favor of ABVD + INRT; the U group, 92.1% versus 89.6% (HR, 1.45; 95% CI, 0.8 to 2.5) in favor of ABVD + INRT. For both F and U groups, noninferiority of ABVD only compared with combined modality treatment could not be demonstrated. Conclusion In stage I and II HL, PET response after two cycles of ABVD allows for early treatment adaptation. When ePET is positive after two cycles of ABVD, switching to BEACOPPesc + INRT significantly improved 5-year PFS. In ePET-negative patients, noninferiority of ABVD only could not be demonstrated: risk of relapse is increased when INRT is omitted, especially in patients in the F group.
Phase I pharmacokinetic (PK) &amp; pharmacogenetic study of sequential infusional irinotecan (IR) and fluorouracil (FU)
Authors: J. L. Grem, M. Wright, G. Morrison, P.-X. Lin, G. Leonard, D. Nguyen, X.-D. Guo, E. Szabo
Journal: Journal of Clinical Oncology (2004)

2075 Background: Preclinical studies show that initial exposure to IR prior to FU is superior to concurrent exposure or the reverse sequence. IR given over 24h may be better tolerated than 0.5–1.5h infusions. Methods: 32 patient (pts) with GI tract cancers participated. IR was initially given at 4 levels (70–140 mg/m2/24h ) followed by LV 500 mg/m2/0.5h & FU 2000 mg/m2/48h starting d 1 & 15 of a 4-wk cycle. FU was then increased in 3 cohorts up to 3900 mg/m2/48h. Dose adjustments (incr./decr.) were based on individual pts toxicity. Plasma levels (Cp) of IR & FU were measured by HPLC & fluorescence or UV detection. Promoter polymorphisms in UGT1A1 & thymidylate synthase (TS) were measured by PCR of genomic DNA & DNA sequencing or agarose gel electrophoresis. Results: 2 pts had dose-limiting toxicity (DLT) during the first complete cycle at 140/3900 of IR/FU (2wk delay for ANC recovery; gr 3 nausea despite antiemetics), while 1/6 pts at 140/3120 had DLT (gr 3 diarrhea, gr 4 ANC). For 60 cycles (9 pts) at 140/3120 IR/FU, the # cycles with DLTs included gr 4 ANC, 1; gr 3 diarrhea, 1; gr 3 fatigue, 1. Overall per pt toxicities included: gr 2/3 diarrhea, 4/4; gr 2/3 stomatitis, 3/0; gr 3/4 AGC, 8/4; no pt had acute cholinergic symptoms. 4/22 pts with colorectal cancer had confirmed partial responses (PR); 2 of these had prior bolus IR/FU. Cpss 5-FU averaged 3.2 (2000), 3.2 (2500), 4.4 (3120) & 5.1 μM (3900 mg/m2/48h). The mean Cp values for IR are shown below. The ratio of free to SN-38G was lower in 9 pts with a (TA)6/6 genotype than in 21 pts with ≥ 1 (TA)7 alleles (0.22 v. 0.35, p=0.037). The distribution of TS genotypes for the 28-base repeat were 2/2 (13%), 2/3 (74%), 3/3 (13%); all 4 PR pts had the 2/3 genotype. Conclusions: Doses (mg/m2) of IR 140/24h, LV 500/0.5h & FU 3120/48hr starting days 1&15 every 4wks are well tolerated. Analyses of extended IR PK sampling & pharmacodynamic correlations are ongoing. No significant financial relationships to disclose.
A Phase II LYSA Study of Obinutuzumab Combined with Lenalidomide for Relapsed or Refractory Aggressive B-Cell Lymphoma
Authors: Franck Morschhauser, Guillaume Cartron, Gilles A. Salles, Fontanet Bijou, Christophe Fruchart, Krimo Bouabdallah, Pierre Feugier, Steven Le Gouill, Hervé Tilly, Cecile moluçon-Chabrot, Marie Maerevoet, Rene-Olivier Casasnovas, Eric W Van Den Neste, Pierre Zachee, Koen Van Eygen, Achiel Van Hoof, Christophe Bonnet, Corinne Haioun, Marc Andre, Luc Xerri, Roch Houot
Journal: Blood (2016)
Management of pain in patients (PTS) receiving active therapy for cancer
Authors: E. Campora, M. Schellino, F. Ardissone, A. Balbo, A. Bandiera, M. Borea, S. Cimino, M. Floccia, M. Mura, F. Salamone, A. Di Lonardo
Journal: Journal of Clinical Oncology (2007)

19645 Background: The World Health Organization (WHO) estimates suggest that moderate to severe pain is experienced by one- third of pts receiving active therapy for their disease and by 60–90% of patients with advanced disease. Procedures that make pain assessment and effective management strategies a routine part of every patient care are recommended. The aim of this study was to integrate nursing intervention with physician management of cronic cancer pain experienced by pts receiving active therapy for cancer. Methods: An Oncology Nurse measured pain in all patients (universal screening) presenting at the Day Hospital for active therapy. Pain was measured using a validated instrument: the Visual Analog Scale (VAS). The pain intensity VAS scale is a 10 cm line anchored on either end by the terms least possible pain and worst possible pain. In addition. the Memorial Pain Assessment Care (MPAC) that consists of 3 VAS scales that measure pain intensity, pain relief and mood and a set of pain severity descriptors adapted from the Tursky rating scale was used. Results: From April 2004 to June 2006 a total of 704 pts were evaluated for pain, 334 (47%) males and 370 (53 %) females with median age 65 years (range 19–85). Results of pain measurement can be synthesized as follows: Pts with VAS = 4 were referred to the oncologist on the same day that pain was measured and analgesics were prescribed according to intensity and type of pain. Conclusions: Results indicate that pain can be universally evaluated and successfully managed in an Oncology Day Hospital. Assessment and treatment of cancer pain should be integrated into routine cancer care. Intervention by the oncology nursing staff is an integral part of effective cancer pain management. No significant financial relationships to disclose. [Table: see text]
The signature program, a series of tissue-agnostic, mutation-specific signal finding trials.
Authors: Eric Daniel Slosberg, Barinder Kang, J. Thaddeus Beck, Sarina Anne Piha-Paul, Robert J. Green, Donald A. Richards, Christopher L. Corless, Donald A. Berry, Steven H. Stein, August J. Salvado
Journal: Journal of Clinical Oncology (2014)

TPS2646^ Background: Here we are introducing a novel signal-finding clinical trial protocol series, termed the Novartis “Signature” program. These are tissue-agnostic, mutation specific protocols that do not include pre-identified clinical trial sites. In part these are responsive to the increased frequency of molecular profiling in the oncology community, and the incidence of patients whose tumors are identified with actionable mutations yet without access to drugs targeting those alterations. As these patients are identified via routine physician-directed profiling, we bring the ‘Protocol to the Patient’, utilizing a rapid study start-up process, such that a de novo site can have one of these trials opened within weeks of the originating patient being identified. Methods: The core of this rapid start-up process includes mandating the use of a non-negotiable standard contract, budget and informed consent, and the use of central IRB. We allow any research experienced site in the US accepting our study model and with a pre-identified patient to participate. The primary endpoints of these trials are to assess clinical benefit associated with study compound. A novel statistical design is incorporated to adaptively cluster patients of like indications into cohorts for independent analysis for futility or efficacy, with subsequent consideration of the initiation of confirmatory trials. Currently the 5 open protocols include buparlisib (PI3Ki), dovitinib (multi-kinase inhibitor), binimetinib (MEK162, MEKi), encorafenib (LGX818, RAFi) and sonidegib (LDE225; SMOi) [NCT01833169, NCT01831726, NCT01885195, NCT01981187 and NCT02002689]. 5 additional single agent and novel-novel protocols are planned to open in 2014. At the time of this submission, 73 patients have been consented at 46 network, academic, and community sites. The average time from a new site approaching Novartis with a potential patient, through site start-up activities, to patient consent and screening, was 4 weeks. This program should enable the enrollment of molecularly profiled patient populations with mutations linked to targeted agents, with expedited timelines, and the evaluation of clinical activity in these (potentially rare) populations. Clinical trial information: NCT01833169, NCT01831726, NCT01885195, NCT01981187 and NCT02002689.
Direct Comparison of Cardiac Myosin-Binding Protein C With Cardiac Troponins for the Early Diagnosis of Acute Myocardial Infarction
Authors: Thomas E. Kaier, Raphael Twerenbold, Christian Puelacher, Jack Marjot, Nazia Imambaccus, Jasper Boeddinghaus, Thomas Nestelberger, Patrick Badertscher, Zaid Sabti, Maria Rubini Giménez, Karin Wildi, Petra Hillinger, Karin Grimm, Sarah Loeffel, Samyut Shrestha, Dayana Flores Widmer, Janosch Cupa, Nikola Kozhuharov, Òscar Miró, F. Javier Martín-Sánchez, Beata Morawiec, Katharina Rentsch, Jens Lohrmann, Wanda Kloos, Stefan Osswald, Tobias Reichlin, Ekkehard Weber, Michael Marber, Christian Mueller
Journal: Circulation (2017)

Cardiac myosin-binding protein C (cMyC) is a cardiac-restricted protein that is more abundant than cardiac troponins (cTn) and is released more rapidly after acute myocardial infarction (AMI). We evaluated cMyC as an adjunct or alternative to cTn in the early diagnosis of AMI.
Thromboembolic events in breast cancer patients: A large series.
Authors: Danilo Souza Reboucas, Luiz Claudio Santos Thuler, Maria Eduarda Ferro Costa, Alvaro Henrique Ingles Garces, Luciana Carla Martins de Aquino, Jose Bines
Journal: Journal of Clinical Oncology (2013)

9589 Background: Breast cancer is frequently associated with thromboembolic events (TEE). TEE may result in significant morbidity, a substantial economic burden and they represent a leading cause of death. Methods: We conducted a case-control study to analyze patients’ baseline and treatment characteristics in predicting TEE occurrence as well as the prognosis of breast cancer patients with thromboembolic events. We identified all breast cancer patients with a TEE at INCA (Brazilian National Cancer Institute), between January 2007 and December 2011. The control group consisted of breast cancer patients that had a doppler ultrasound with normal findings during the same period. Variables found to be significant (P &lt;0.10) by univariate analysis were subsequently entered into a multivariate logistic regression model. We used Kaplan-Meier and Cox regression for survival analysis. Results: Overall, 225 patients that developed TEE were compared to 225 matched controls. The majority of events were deep vein thrombosis of the lower extremity (78.7%) and unilateral (94.2%). Most TEE occurred within the first 3 years after the diagnosis of cancer (66.2%), with the highest incidence observed in the initial 6 months. Factors associated with the development of TEE were: age above 50 years (OR 1.85, 95% CI: 1.16 to 2.95), ECOG performance status (PS) equal to or above 3 (OR 2.01, CI 95%: 1.24 to 3.26) and the presence of a central venous catheter (CVC) (OR 2.56, 95% CI: 1.42 to 4.62). The occurrence of TEE led to systemic treatment changes (44.9%) and, most importantly, it was associated with decreased survival (HR = 1.34, 95% CI: 1.01 to 1.77, p = 0.041). Conclusions: This large retrospective analysis of TEE in breast cancer patients confirms that most events occur early in the treatment course. The incidence of TEE was associated with patients’ age, PS, and the presence of CVC. Prospective studies are needed to evaluate outpatient thromboprophylaxis for selected groups of patients.